Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 7/20 | 0.56 |
| ▸ | GABRA5 | P31644 | 13/20 | 0.53 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL286422 | 0.89 | GABRA5 (0.64) | HCAR3GABRA5 | |
| SCHEMBL285474 | 0.87 | GABRA5 (0.66) | GABRA5 | |
| SCHEMBL286255 | 0.85 | GABRA5 (0.59) | HCAR3GABRA5 | |
| SCHEMBL285422 | 0.84 | GABRA5 (0.55) | GABRA5 | |
| SCHEMBL285420 | 0.82 | GABRA5 (0.69) | GABRA5 | |
| SCHEMBL103674 | 0.79 | GABRA5 (0.60) | GABRA5 | |
| SCHEMBL2933116 | 0.78 | GABRA5 (0.82) | GABRA5 | |
| SCHEMBL14797029 | 0.74 | HCAR3 (0.41) | HCAR3GABRA5 | |
| SCHEMBL14797027 | 0.74 | HCAR3 (0.41) | HCAR3GABRA5 | |
| SCHEMBL22047713 | 0.73 | HCAR3 (1.00) | HCAR3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427457-B1 | ISOXAZOLE-PYRIDINE DERIVATIVES AS GABA MODULATORS | HOFFMANN LA ROCHE (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-8357703-B2 | Pyridines | HOFFMANN-LA ROCHE INC. (US) | 2013-01-22 | — | — | US | disclosed |
| EP-2427457-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES AS GABA MODULATORS | F. Hoffmann-La Roche AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010127978-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES AS GABA MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286117-A1 | PYRIDINES | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286117-A1 | PYRIDINES | GABRA5, GABRA1, GABRA4 | HCAR3 110/4885GABRA5 1/4885HCAR2 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.